Trial for early uterine cancer with POLE mutation after surgery
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial studies an added (adjuvant) treatment for early-stage uterine cancer that has a specific genetic change called POLE mutation and does not have a p53 abnormal pattern. The goal is to lower the risk of the cancer coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove the uterus (hysterectomy) and both ovaries and fallopian tubes (bilateral salpingo-oophorectomy), with no visible leftover cancer after surgery
- Your uterine cancer was diagnosed as Stage I to III, and the tissue type can include endometrioid, serous, clear cell, undifferentiated, carcinosarcoma, or mixed types
- Your overall health score (ECOG) is 0, 1, or 2 (able to do daily activities with limited help)
- You must be at least 18 years old and able to give consent and complete questionnaires in English or French (or an approved language)
- Treatment must start within 10 weeks after your surgery, and you must be able to come for care and follow-up at the trial hospital
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using tumor “molecular” results plus standard risk factors can guide the best type and timing of radiation after surgery for early-stage endometrial cancer. It may help you avoid under- or overtreatment by matching radiotherapy to your specific risk.
This trial studies which after-surgery (adjuvant) treatment works best when endometrial cancer is classified by specific tumor DNA/molecular features. You may be offered treatment based on the tumor results, aiming to improve outcomes and lower the risk of the cancer coming back.
This trial studies giving radiation after surgery for certain early-stage uterine (endometrial) cancer types. It may help lower the chance the cancer comes back, especially for higher-grade cases.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial compares different “fractionation” schedules (how often and how many treatments) of vaginal brachytherapy radiation given after surgery for certain early-stage endometrial cancer. It may help find a plan that works well while aiming to control side effects.
This trial tests a precise type of radiation (stereotactic radiotherapy) given after surgery for endometrial cancer. It aims to improve treatment while reducing side effects.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.